Faricimab reduces fluid in Neovascular Age-Related Macular Degeneration eyes, unravels study
Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 years old. Anti-vascular endothelial growth factor (anti-VEGF) therapies for macular neovascularization have been pivotal in decreasing the number of individuals visually impaired by neovascular age-related macular degeneration (nARMD). Faricimab is a novel antibody for the treatment of nARMD that aims to neutralize not only VEGF-A but also Angiopoietin-2 (Ang-2), thus targeting two distinct pathways involved in nARMD pathogenesis. Faricimab was initially shown to be non-inferior to aflibercept in terms of change in best corrected visual acuity (BCVA) at one year for treatment-naïve individuals. Many patients were also able to achieve long dosing intervals of 12 or 16 weeks on faricimab.
This study aimed to collect functional and optical coherence tomography (OCT)-based morphological observations after faricimab treatment in a particular subset of eyes that showed persistent subretinal and/or intraretinal fluid despite previous treatment with at least two other anti-VEGF agents. Authors hypothesized that eyes refractory to treatment with multiple prior anti-VEGF agents may still be able to respond anatomically and/or functionally to faricimab injections based on the novel mechanistic nature of the antibody.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.